Improvement glucose-induced insulin secretion diabetic rats long-term gliclazide treatment comparative study different models non-insulin-dependent diabetes mellitus neonatal streptozotocin Understanding long-term action sulfonylureas humans non-insulin-dependent diabetes NIDDM effect long-term sulfonylurea administration animal models disease study different versions neonatal streptozotocin-induced diabetes STZ model NIDDM model STZ day birth basal hyperglycemia marked reduction pancreatic insulin stores insulin resistance model STZ day birth mild hyperglycemia reduction pancreatic insulin content insulin resistance diabetic rats oral gliclazide mg/kg/day untreated diabetic rats nondiabetic rats Insulin secretion day last gliclazide isolated perfused pancreas preparation severely hyperglycemic rats glucose levels mmol/L long-term gliclazide treatment plasma glucose values pancreatic insulin stores vitro insulin release response hyperglycemic rats glucose levels mmol/L plasma glucose levels mean mmol/L end gliclazide therapy increase pancreatic insulin stores rats marginal rats treatment plasma glucose levels pancreatic insulin stores gliclazide therapy gliclazide responder group group vitro glucose-induced insulin secretion three- response diabetic rats two- insulin release response unchanged conclusion long-term gliclazide therapy augments insulin secretion rat models NIDDM refractoriness short-term sulfonylurea administration improvement beta-cell function concomitant variations hyperglycemia and/or pancreatic insulin content 